CDK Inhibitors approved by PBAC 20 April 2018
CDK Inhibitors approved by the Pharmaceutical Benefits Advisory Committee (PBAC) but cost is still an issue. See the link below for further information https://www.bcna.org.au/news/2018/04/cdk-i...
Forum Discussion
Mildly interesting - especially the last paragraph - that indirectly points to recycling of therapies in some patients.
https://www.onclive.com/web-exclusives/cdk46-inhibition-refined-in-hr-breast-cancer-as-novel-combos-emerge?p=2
https://www.onclive.com/web-exclusives/cdk46-inhibition-refined-in-hr-breast-cancer-as-novel-combos-emerge?p=2